

**SPECIALISED COMMISSIONING - CLINICAL EVIDENCE EVALUATION  
CRITERIA FOR A PROPOSITION FOR A CLINICAL COMMISSIONING POLICY  
FOR ROUTINE COMMISSIONING**

URN: A06X03

TITLE: Eculizumab for the treatment of recurrence in C3 glomerulopathy post-kidney transplant

CRG: Renal dialysis

NPOC: Internal medicine

Lead: Ursula Peaple

Date: 18/1/16

The panel were presented a policy proposal for routine commissioning

<b>Question</b>	<b>Conclusion of the panel</b>	<b>If there is a difference between the evidence review and the policy please give a commentary</b>
<p><u>The population</u></p> <p>1. Are the eligible and ineligible populations defined in the policy consistent with the evidence of effectiveness, and evidence of lack of effectiveness; and where evidence is not available for the populations considered in the evidence review?</p>	<p>The eligible population(s) defined in the policy are the same or similar to the population(s) for which there is evidence of effectiveness considered in the evidence review</p>	
<p><u>Population subgroups</u></p> <p>2. Are any population subgroups defined in the policy and if so do they match the subgroups considered by the evidence review?</p>	<p>The population subgroups defined in the policy are the same or similar as those for which there is evidence in the evidence review</p>	
<p><u>Outcomes - benefits</u></p> <p>3. Are the clinical benefits demonstrated in the evidence</p>	<p>The clinical benefits demonstrated in the</p>	

<p>review consistent with the eligible population and/or subgroups presented in the policy?</p>	<p>evidence review support the eligible population and/or subgroups presented in the policy</p>	
<p><u>Outcomes – harms</u></p> <p>4. Are the clinical harms demonstrated in the evidence review reflected in the eligible and / or ineligible population and/or subgroups presented in the policy?</p>	<p>The clinical harms demonstrated in the evidence review are reflected in the eligible population and/or subgroups presented in the policy</p>	
<p><u>The intervention</u></p> <p>5. Is the intervention described in the policy the same or similar as the intervention for which evidence is presented in the evidence review?</p>	<p>The intervention described in the policy the same or similar as in the evidence review</p>	
<p><u>The comparator</u></p> <p>6. Is the comparator in the policy the same as that in the evidence review?</p> <p>7. Are the comparators in the evidence review the most plausible comparators for patients in the English NHS and are they suitable for informing policy development.</p>	<p>The comparator in the policy is the same as that in the evidence review.</p> <p>The comparators in the evidence review include plausible comparators for patients in the English NHS and are suitable for informing policy development.</p>	
<p><u>Advice</u></p> <p>The Panel should provide advice on matters relating to the evidence base and policy development and prioritisation. Advice may cover:</p> <ul style="list-style-type: none"> <li>• Uncertainty in the evidence</li> </ul>		<p>The Panel supported the policy statement and that the findings of the clinical evidence review and should progress.</p>

<p>base</p> <ul style="list-style-type: none"> <li>• Challenges in the clinical interpretation and applicability of policy in clinical practice</li> <li>• Challenges in ensuring policy is applied appropriately</li> <li>• Issues with regard to value for money</li> <li>• Likely changes in the pathway of care and therapeutic advances that may result in the need for policy review.</li> </ul>		
--	--	--

Overall conclusions of the panel

The policy is supported and should proceed.

Report approved by:  
James Palmer  
Clinical Panel Chair  
18/1/16

For public consultation